Neurodegeneration has often been described through its endpoints: tangles, Lewy bodies, TDP-43 inclusions, huntingtin aggregates, and amyloid plaques. These structures dominate our understanding because they are prominent in pathology. However, the visible aggregates are merely remnants of an earlier collapse within cellular environments.

Over the last decade, it has become evident that proteins associated with Alzheimer's, Parkinson's, ALS/FTD, and Huntington's disease do not just misfold; they transition. They move from disorder to concentration, from condensation to viscosity, and finally crystallize into fibrils after crossing several metastable states.

These transitions follow a deeply conserved pattern, almost archetypal. For proteins like tau, α-synuclein, TDP-43, FUS, huntingtin, and even the peptide Aβ, pathology progresses through a phase architecture rather than a linear aggregation pathway. The cell fails through states, each with distinct characteristics and therapeutic possibilities.

1. The Common Language of Disordered Proteins

All major neurodegenerative proteins are intrinsically disordered, consisting of low-complexity sequences that lack fixed structures and instead exist in broad conformational ensembles. This disorder is not a random occurrence; it allows flexibility, rapid binding, multivalency, and participation in dynamic molecular environments like RNA granules and synaptic terminals.

Disorder also brings susceptibility to phase separation. When protein interactions involving charged residues, aromatic clusters, and β-prone motifs exceed a threshold, the protein separates into a dense, liquid-like phase, where protein concentration dramatically increases, altering the energy landscape and allowing new structures.

This is where disease begins—within condensed intermediates that create environments for new configurations, otherwise impossible in the dilute cytoplasm.

2. Tau: A Textbook on How a Protein Traverses Phases

Tau provides a clear example, with transitions observed through various modalities (SAXS, FRET, NMR, cryo-EM).

• The Soluble Ensemble (Phase 0)
  • Tau starts as an extended statistical coil maintained by long-range electrostatic interactions, known as the "paperclip" conformation. This structure shields the amyloidogenic fragments, PHF6 and PHF6*, from each other. Any disruption of these contacts—via phosphorylation, MAPT mutations, or oxidative changes—prepares tau for the next state.
• Nanoclusters (Phase 1)
  • This phase often goes unnoticed as it is invisible to routine biology. However, small-angle scattering reveals that tau first condenses into soft nanoclusters just a few nanometers across. These clusters are held together by electrostatic interactions, not droplets or fibrils, but transient groupings.
    • The key insight is that if these nanoclusters dissolve, fibrils do not form. This initial state change is essential.
• Liquid Droplets (Phase 2)
  • With triggers like heparin, RNA, polyphosphate, tubulin, or crowding, tau transitions into micron-sized droplets. These droplets behave dynamically: they fuse, deform, and exchange components with the cytoplasm. Within them, tau becomes concentrated, exposing PHF6 segments and expanding the conformational landscape.
    • Inside droplets, tau exists in a different realm, governed by new physics.
• Aging (Phase 3)
  • Droplets are unstable. Over time, they stiffen, viscosity increases, FRAP recovery slows, and they start losing their liquid nature.     This "aging" is speeded up by phosphorylation, mutations, and stress—anything disrupting the electrostatic balance.
    • The aged droplet is the most perilous state in tau biology, where reversibility gives way to irreversible structure.
• Nucleation and Fibril Growth (Phases 4-6)
  • Within aged droplets, tau nucleates into β-rich protofibrils, elongating into paired helical filaments. As fibrils grow, the droplet collapses, expelling water and forming the dense, tangled masses seen in Alzheimer's, PSP, and CBD.
  • The tangle originates as a liquid.

3. α-Synuclein: The Parkinsonian Mirror Image

α-Synuclein follows a similar architecture.

• Early State
  • This protein is a disordered monomer, amphipathic, capable of membrane binding but otherwise structurally free.
• Nanoclusters & Early Oligomers
  • Triggered by acidic pH, metal ions, lipids, or familial mutations (A53T, E46K), α-synuclein forms dynamic nanoclusters and oligomeric seeds.
• Droplet Formation
  • At higher concentrations or in charged environments, it undergoes LLPS, forming droplets with rapid internal exchange.
• Droplet Aging
  • Over time, droplets become slow-moving, viscoelastic gels with increasing β-structure.
• Pathological Collapse
  • Within these aged condensates, protofibrils form, and the droplet eventually collapses into the layered architecture of the Lewy body, containing lipids and vesicles.

This layered inclusion is more than an aggregate—it is the fossilized end-state of a collapsed liquid.

4. TDP-43: Stress, RNA, and the Drift Toward Irreversibility

TDP-43 begins as a functional RNA-binding protein in the nucleus.

• Mislocalization and Nanoclusters
  • When nuclear import fails or stress drives TDP-43 to the cytoplasm, it forms early nanoclusters—small, disordered, and reversible.
• Stress Granule LLPS
  • Within stress granules, TDP-43 undergoes LLPS, with its prion-like domain facilitating fluid droplet formation.
• Aging and Chronic Stress
  • Under chronic stress or ALS-linked mutation, these droplets lose liquidity, RNA dissociates, and the environment becomes conducive to nucleation.
• Inclusion Formation
  • Protofibrils emerge, leading to the hardened, ubiquitinated, phosphorylated structures characteristic of ALS and FTD.

5. FUS: A Condensate That Loses Its Passport

FUS depends on phase separation for normal nuclear RNA activities. When its nuclear import signal is compromised:

• it mislocalizes
• forms cytoplasmic droplets
• ages rapidly
• transitions into hydrogels
• solidifies into fibrils

FUS condensates fail because the protein is removed from the regulatory systems—Transportin/Kapβ2, methylation, chaperones—that usually control its liquidity.

6. Huntingtin: PolyQ as a Solvent for Its Own Collapse

Huntingtin's N-terminal exon1 fragment exhibits LLPS when polyQ expansions exceed a threshold. These droplets age into gel-like foci, then nucleate into β-rich fibrils, forming intranuclear inclusions.

The logic remains: pathological structure only emerges after passing through an intermediate condensed state.

7. Aβ: A Smaller Protein, Same Architecture

Despite its size and extracellular location, Aβ also forms:

• nanoclusters
• coacervate-like condensates
• protofibrils from dense microenvironments

The plaque is simply the terminal state of a condensed intermediate that can no longer remain dynamic.

8. The Shared Architecture of Failure

Across all proteins, the sequence is conserved:

1. Disordered monomer
2. Transient nanocluster
3. Liquid droplet
4. Viscoelastic gel
5. β-rich nucleus
6. Fibril/inclusion

The progression is from fluidity to constraint to crystallization. The pathology is not the fibril itself; it's the loss of reversible liquidity.

This is the common physics of neurodegeneration.

9. What This Means Clinically

The therapeutic target—if these diseases are to be altered significantly—lies in the transitional states, not the terminal aggregates.

We must focus on:

• preventing nanocluster formation
• reducing LLPS propensity
• maintaining droplet liquidity
• preventing gelation
• blocking the conversion from aged droplet to β-nucleus

Interventions at any later stage become fundamentally reactive.

We have been treating the shadows, not the event that casts them.

10. Closing Reflection

The proteins we once viewed as malfunctioning machines are dynamic liquids navigating phase space. Neurodegeneration occurs when these liquids lose their ability to remain fluid—when regulation fails, stress accumulates, mutations alter the phase diagram, and the cell's buffering capacities are overwhelmed.

These diseases are not merely disorders of folding. They are disorders of state, phase integrity, and the delicate balance between fluidity and form.

To intervene, we must act while the system still remembers how to flow.

References

1. Ambadipudi, S., Biernat, J., Riedel, D., Mandelkow, E., & Zweckstetter, M. (2017). Liquid–liquid phase separation of the microtubule-binding repeats of the Alzheimer-related protein tau. Nature Communications, 8, 275. https://doi.org/10.1038/s41467-017-00480
2. Proceedings of the National Academy of Sciences, 116Despres, C., Byrne, C., Qi, H., Cantrelle, F.-X., Huvent, I., Chambraud, B., ... Landrieu, I. (2019). Identification of the tau phosphorylation pattern that drives its aggregation. (16), 7503–7512.
3. Proceedings of the National Academy of Sciences, 115Fichou, Y., Lin, Y., Rauch, J. N., Vigers, M., Zeng, Z., Srivastava, M., ... Kosik, K. S. (2018). Cofactors are essential constituents of stable and seeding-active tau fibrils. (52), 13234–13239.
4. Brain Pathology, 28Hasegawa, M., Nonaka, T., & Masuda-Suzukake, M. (2017). Molecular mechanisms of tau aggregation and spread. (6), 965–974.
5. Science, 357Shin, Y., & Brangwynne, C. P. (2017). Liquid phase condensation in cell physiology and disease. (6357), eaaf4382.
6. Neuroscience Research, 220Takahashi, T., Nonaka, T., Ohtani, R., Hasegawa, M., Hori, Y., Tomita, T., & Kurita, R. (2025). Hindering tau fibrillization by disrupting transient precursor clusters. , 104968. https://doi.org/10.1016/j.neures.2025.104968
7. The EMBO Journal, 37Wegmann, S., Eftekharzadeh, B., Tepper, K., Zoltowska, K. M., Bennett, R. E., Dujardin, S., ... Hyman, B. T. (2018). Tau protein liquid–liquid phase separation can initiate tau aggregation. (7), e98049.
8. PLOS Biology, 15Zhang, X., Lin, Y., Eschmann, N. A., Zhou, H., Rauch, J. N., Hernandez, I., ... Kosik, K. S. (2017). RNA stores tau reversibly in complex coacervates. (7), e2002183.
9. Journal of Biological Chemistry, 294Araki, K., Yagi, N., Nakatani, R., & Mochizuki, H. (2019). Metal ions modulate liquid–liquid phase separation and aggregation of α-synuclein. (50), 19506–19515.
10. Journal of Molecular Biology, 433Hardenberg, M. C., Sinnige, T., Casford, S. T., Dada, S., Poudel, C., Robinson, E. A., ... Kaminski Schierle, G. S. (2021). Observation of α-synuclein liquid–liquid phase separation in vitro. (22), 167078.
11. Biochemical and Biophysical Research Communications, 534Huang, C., Ren, G., Zhou, H., Wang, K., & Min, J. (2021). Calcium promotes α-synuclein liquid–liquid phase separation. , 549–555.
12. Nature Chemistry, 12Ray, S., Singh, N., Kumar, R., Patel, K., Pandey, S., Datta, D., ... Maji, S. K. (2020). α-Synuclein aggregation nucleates through liquid–liquid phase separation. , 705–716. https://doi.org/10.1038/s41557-020-0465-9
13. Journal of Biological Chemistry, 294Babinchak, W. M., Haider, R., Sarkar, P., Pattabiraman, M., Vijayaraghavan, N., Bellotti, V., & Surewicz, W. K. (2019). The role of liquid–liquid phase separation in aggregation of the TDP-43 low-complexity domain. (16), 6306–6317.
14. Proceedings of the National Academy of Sciences, 117Conicella, A. E., Dignon, G. L., Zerze, G. H., Schmidt, H. B., D’Ordine, A. M., Kim, Y. C., ... Fawzi, N. L. (2020). TDP-43 α-helical structure tunes liquid–liquid phase separation and function. (11), 5883–5894.
15. Acta Neuropathologica, 126Mackenzie, I. R. A., Nicholson, A. M., Van Deerlin, V. M., et al. (2013). TDP-43 pathology in ALS and FTLD. , 125–147.
16. Cell, 163McGurk, L., Gomes, E., & Shorter, J. (2015). RNA-dependent phase transitions in neurodegenerative disease. (1), 7–8.
17. Cell, 149Han, T. W., Kato, M., Xie, S., Wu, L. C., Mirzaei, H., Pei, J., ... McKnight, S. L. (2012). Cell-free formation of RNA granules: Bound RNAs identify features and components of cellular assemblies. (4), 768–779.
18. Foundational demonstration of FUS LLPS.()
19. Cell, 173Hofweber, M., Hutten, S., Bourgeois, B., Spreitzer, E., Niedner-Benrath, M., Schifferer, M., ... Dormann, D. (2018). Phase separation of FUS is suppressed by its nuclear import receptor and arginine methylation. (3), 706–719.
20. Neuron, 88Murakami, T., Qamar, S., Lin, J. Q., Schierle, G. S., Rees, E., Miyashita, A., ... Holt, C. E. (2015). ALS/FTD mutation-induced phase transition of FUS liquid droplets into irreversible fibrils. (4), 678–690.
21. Cell, 162Patel, A., Lee, H. O., Jawerth, L., Maharana, S., Jahnel, M., Hein, M. Y., ... Alberti, S. (2015). A liquid-to-solid phase transition of the ALS protein FUS accelerated by disease mutation. (5), 1066–1077.
22. Molecular Cell, 70Peskett, T. R., Rau, F., O’Driscoll, J., Patani, R., Lowe, A. R., & Saibil, H. R. (2018). A liquid-to-solid phase transition underlying pathological huntingtin exon1 aggregation. (4), 588–601.e6.
23. Current Opinion in Structural Biology, 50Posey, A. E., Holehouse, A. S., & Pappu, R. V. (2018). Phase separation of intrinsically disordered proteins contributes to polyQ aggregation. , 111–122.
24. Biochemical Society Transactions, 48Zhang, Q., Xu, W., & Xu, G. (2020). Liquid–liquid phase separation as an organizing principle of the cellular stress response and polyQ pathology. (4), 1597–1606. 
25. Proceedings of the National Academy of Sciences, 117Cheng, S., Brooks, B. R., & Hummer, G. (2020). Coacervation and amyloid formation of Aβ peptides. (36), 21950–21956.
26. Acta Neuropathologica Communications, 9Saito, M., Shinohara, M., & Iwatsubo, T. (2021). Amyloid-β oligomers as a liquid-like state: Implications for plaque nucleation. , 28.
27. Scientific Reports, 6Watanabe-Nakayama, T., Takeuchi, H., & Uematsu, K. (2016). Structural dynamics of amyloid β protein assembly. , 19577.
28. Developmental Cell, 55Alberti, S., & Hyman, A. A. (2021). Biomolecular condensates at the nexus of cellular stress, protein aggregation, and neurodegeneration. (1), 22–46.
29. Trends in Cell Biology, 28Boeynaems, S., Alberti, S., Fawzi, N. L., Mittag, T., Polymenidou, M., Rousseau, F., ... Van Den Bosch, L. (2018). Protein phase separation: A new phase in cell biology. (6), 420–435.
30. Reports on Progress in Physics, 83Dignon, G. L., Best, R. B., & Mittal, J. (2020). Biomolecular phase separation: A primer for physicists. (4), 046601.
31. Journal of Biological Chemistry, 294Gomes, E., & Shorter, J. (2019). The molecular language of membraneless organelles. (18), 7115–7127.
32. Nature Reviews Neurology, 18Laflamme, G., & Mekhail, K. (2022). Biomolecular condensates as integrators of phase transitions in neurodegenerative disease. , 297–312.
33. Science, 357Shin, Y., & Brangwynne, C. P. (2017). Liquid phase condensation in cell physiology and disease. (6357), eaaf4382.
34. Nature Reviews Molecular Cell Biology, 18Banani, S. F., Lee, H. O., Hyman, A. A., & Rosen, M. K. (2017). Biomolecular condensates: Organizers of cellular biochemistry. (5), 285–298.
35. Journal of Cell Biology, 220Snead, W. T., & Gladfelter, A. S. (2019). The control centers of biomolecular phase separation: How membrane surfaces, PTMs, and RNA tune condensates. (4), e202103105.